Patents by Inventor Tanja Herrmann
Tanja Herrmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240018225Abstract: The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer.Type: ApplicationFiled: August 25, 2023Publication date: January 18, 2024Inventors: Julia Neugebauer, Barbara Bachler-Konetzki, Tanja Herrmann, Winfried Elis
-
Publication number: 20220135658Abstract: The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer.Type: ApplicationFiled: March 13, 2020Publication date: May 5, 2022Inventors: Julia NEUGEBAUER, Barbara BACHLER-KONETZKI, Tanja HERRMANN, Winfried ELLIS
-
Patent number: 11292838Abstract: The invention relates to a method for generating an antibody binding to a cell surface protein of interest, the method comprising the following steps: (a) providing a non-human cell which does not express the endogenous form of the cell surface protein of interest but expresses an exogenous form of the cell surface protein of interest comprising at least one human segment; (b) immunization of a non-human animal with the cell line provided in step (a); (c) generation of hybridomas from the immunized non-human animal of step (b); (d) screening for an antibody that binds to the cell surface protein of interest by contacting the antibodies secreted by the hybridomas of step (c) with human cells which do not express the endogenous form of the cell surface protein of interest but express an exogenous form of the cell surface protein of interest comprising at least one human segment.Type: GrantFiled: June 1, 2016Date of Patent: April 5, 2022Assignee: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Dolores Schendel, Slavoljub Milosevic, Tanja Herrmann, Michaela Kügler
-
Patent number: 10647757Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.Type: GrantFiled: March 3, 2017Date of Patent: May 12, 2020Assignee: MORPHOSYS AGInventors: Markus Enzelberger, Stefanie Urlinger, Thomas Tiller, Josef Prassler, Tanja Herrmann
-
Publication number: 20180256716Abstract: The present invention relates to an antibody or binding fragment thereof that binds to a fraction of T cell receptor variable alpha (TCR V?) chains comprising at least two different TCR V? chains but less than all TCR V? chains or that binds to a fraction of T cell receptor variable beta (TCR V?) chains comprising at least two different TCR V? chains but less than all TCR V? chains.Type: ApplicationFiled: June 1, 2016Publication date: September 13, 2018Inventors: Dolores SCHENDEL, Slavoljub MILOSEVIC, Tanja HERRMANN, Michaela KÜGLER
-
Publication number: 20180237520Abstract: The invention relates to a method for generating an antibody binding to a cell surface protein of interest, the method comprising the following steps: (a) providing a non-human cell which does not express the endogenous form of the cell surface protein of interest but expresses an exogenous form of the cell surface protein of interest comprising at least one human segment; (b) immunization of a non-human animal with the cell line provided in step (a); (c) generation of hybridomas from the immunized non-human animal of step (b); (d) screening for an antibody that binds to the cell surface protein of interest by contacting the antibodies secreted by the hybridomas of step (c) with human cells which do not express the endogenous form of the cell surface protein of interest but express an exogenous form of the cell surface protein of interest comprising at least one human segment.Type: ApplicationFiled: June 1, 2016Publication date: August 23, 2018Inventors: Dolores SCHENDEL, Slavoljub MILOSEVIC, Tanja HERRMANN, Michaela KÜGLER
-
Publication number: 20180194846Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.Type: ApplicationFiled: February 27, 2018Publication date: July 12, 2018Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
-
Publication number: 20180134791Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.Type: ApplicationFiled: July 23, 2015Publication date: May 17, 2018Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
-
Publication number: 20170218048Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.Type: ApplicationFiled: March 3, 2017Publication date: August 3, 2017Inventors: Markus Enzelberger, Stefanie Urlinger, Thomas Tiller, Josef Prassler, Tanja Herrmann
-
Patent number: 9624293Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.Type: GrantFiled: January 31, 2014Date of Patent: April 18, 2017Assignee: MORPHOSYS AGInventors: Markus Enzelberger, Stefanie Urlinger, Thomas Tiller, Josef Prassler, Tanja Herrmann
-
Publication number: 20160060347Abstract: This disclosure generally relates to antibodies or fragments thereof which interact with CXCR2. The disclosure further discloses antibodies, which bind to specific extracellular domains of CXCR2. The disclosure further relates to therapeutics comprising CXCR2-specific antibodies and methods of treatment using CXCR2-specific antibodies or fragments thereof.Type: ApplicationFiled: April 15, 2014Publication date: March 3, 2016Inventors: Tanja Herrmann, Andreas Bueltmann
-
Publication number: 20160031993Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.Type: ApplicationFiled: July 23, 2015Publication date: February 4, 2016Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
-
Publication number: 20140163208Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.Type: ApplicationFiled: January 31, 2014Publication date: June 12, 2014Applicant: MorphoSys AGInventors: Markus Enzelberger, Stefanie Urlinger, Thomas Tiller, Josef Prassler, Tanja Herrmann
-
Patent number: 8685896Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.Type: GrantFiled: May 29, 2010Date of Patent: April 1, 2014Assignee: MorphoSys AGInventors: Markus Enzelberger, Stefanie Urlnger, Thomas Tiller, Josef Prassler, Tanja Herrmann
-
Publication number: 20130344091Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.Type: ApplicationFiled: August 29, 2013Publication date: December 26, 2013Applicant: Novartis AGInventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
-
Patent number: 8551482Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.Type: GrantFiled: May 31, 2012Date of Patent: October 8, 2013Assignee: Novartis AGInventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
-
Patent number: 8388968Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.Type: GrantFiled: April 26, 2010Date of Patent: March 5, 2013Assignee: Novartis AGInventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stefanie Urlinger
-
Publication number: 20120237521Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.Type: ApplicationFiled: May 31, 2012Publication date: September 20, 2012Applicant: NOVARTIS AGInventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stefanie Urlinger
-
Publication number: 20120077713Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.Type: ApplicationFiled: May 29, 2010Publication date: March 29, 2012Applicant: MORPHOSYS AGInventors: Markus Enzelberger, Stefanie Urlnger, Thomas Tiller, Josef Prassler, Tanja Herrmann
-
Publication number: 20100272734Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.Type: ApplicationFiled: April 26, 2010Publication date: October 28, 2010Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle TRIFILIEFF, Stefanie Urlinger